Revenue
2020
2021
2022
2023
2024
2025
RxSight, Inc. (RXST)
Price—Loading quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | $134.5M | $139.9M | $89.1M | $49.0M | $22.6M | $14.7M |
| Gross profit | $103.0M | $98.9M | $53.8M | $21.3M | $4.5M | $1.7M |
| Research & development | $38.5M | $34.4M | $29.1M | $26.0M | $24.5M | $21.9M |
| Operating expenses | $151.2M | $135.8M | $103.8M | $84.6M | $57.3M | $37.1M |
| Operating income | −$48.2M | −$36.9M | −$50.1M | −$63.3M | −$52.8M | −$35.4M |
| EBITDAderived | −$44.9M | −$33.3M | −$46.0M | −$59.4M | −$48.8M | −$31.6M |
| Net income | −$38.9M | −$27.5M | −$48.6M | −$66.8M | −$48.7M | $27.6M |
| Basic EPSper diluted share | -$0.95 | -$0.71 | -$1.41 | -$2.41 | -$3.57 | $0.91 |
| Diluted EPSper diluted share | -$0.95 | -$0.71 | -$1.41 | -$2.41 | -$3.57 | $0.15 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Mar 12, 2025Form 4 · 10b5-1 | Fountain TamaraDirector | SellCommon Stock | 7.0K | $25.71 | $180.0K | 24.8K |
| Jan 22, 2025Form 4 · 10b5-1 | Maniar ShwetaDirector | SellCommon Stock | 3.5K | $30.87 | $108.6K | 7.4K |
| Jan 16, 2025Form 4 | Corley Jesse AndersonDirector | BuyCommon Stock · indirect | 1.8K | $31.13 | $55.0K | 3.2K |
| Jan 15, 2025Form 4 | Corley Jesse AndersonDirector | BuyCommon Stock · indirect | 1.4K | $31.19 | $45.0K | 1.4K |
| Nov 29, 2024Form 4 · 10b5-1 | Goldshleger IlyaSee remarks | SellCommon Stock | 3.1K | $46.08 | $143.1K | 42.2K |